Skip to main content

Loncastuximab Tesirine + Rituximab After Radiosurgery

Loncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery in Patients With Central Nervous System Lymphomas (SOLAR)

  • RegistryNCT06607549
  • PhasePhase 1
  • StatusRecruiting
  • ConditionCentral Nervous System Lymphoma
  • SponsorUniversity of Utah
How SOLAR worksNCT066075491 min

What the film says

Read the transcript

This trial is for adults with central nervous system lymphoma that has relapsed, or that is untreated in patients who cannot have high dose methotrexate.

The idea: after stereotactic radiosurgery to the brain, give loncastuximab tesirine and rituximab by vein for six cycles.

This phase 1 study plans 12 patients and looks for a safe, tolerable dose of the combination after radiosurgery. At Huntsman Cancer Institute at the University of Utah, Narendranath Epperla leads it.

Public record; not medical advice.

Sources behind this film

  • ClinicalTrials.gov record NCT06607549

    Adults; CNS lymphoma, relapsed or untreated and not HDM candidates; After SRS, lonca-R IV six cycles; Phase 1; 12 patients; safe tolerable dose; Huntsman Cancer Institute, University of Utah; Narendranath Epperla

The drug

What is being tested.

Patients will receive stereotactic radiosurgery (SRS) followed by a brain MRI approx. 3 weeks after SRS. This will be followed by loncastuximab tesirine and rituximab administered intravenously for a total of 6 cycles (every 21 days).

The study

How the trial runs.

The purpose of this clinical trial is to learn if drugs loncastuximab tesirine and rituximab (lonca-R) after stereotactic radiosurgery are safe and effective for treatment of central nervous system lymphomas.

Live record on ClinicalTrials.gov →

Eligibility

Who the study is looking for.

  • Participant aged ≥ 18 years
  • ECOG Performance Status ≤ 3
  • Relapsed or refractory disease with at least 1 prior therapy OR
  • Ineligible for high-dose methotrexate-based therapy as determined by the treating physician, including previously untreated patients. Examples of medical conditions for which a patient could be considered ineligible for high-dose methotrexate include but not limited to renal impairment, liver disease, heart failure.
  • Note: For patients with a history of histologically documented systemic DLBCL with CNS relapse, a biopsy of the CNS lesion is recommended but not required.

Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.

For you, or someone you love

Whether or not this trial is the one, bring AI into your corner.

A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.

Start your 7-day free trial

Then $9 a month. Cancel anytime.

  • Every record in one place

    Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.

  • Read in plain words

    Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.

  • Ready for every appointment

    Ask about your own file, and walk in with questions for your oncologist or the trial team.

  • Your people, in the loop

    Share one profile with the family helping you, and with your doctors.

Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.

How these trials work: what Phase 1 actually is · common questions Not clinical evidence.